Compare
Abbott Laboratories vs ResMed (ABT vs RMD)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Abbott Laboratories (ABT) returned -11.7% and ResMed (RMD) -4.0%; so far this year the figures are -12.3% and -2.3%.
Abbott Laboratories is the larger company by market value, about 5.8 times the size of ResMed.
On trailing earnings, ABT trades at 40.9 times and RMD at 21.4 times.
Revenue grew +10.0% at ABT and +9.0% at RMD over the last year.
ABT yields 2.29%. RMD yields 1.05%.
Data as of the latest close. Not investment advice.
Relative performance
| ABT | RMD | |
|---|---|---|
| Price | $109.93 | $235.30 |
| 1-day | -3.23% | -1.68% |
| YTD | -12.26% | -2.31% |
| 1 year | -11.73% | -4.05% |
| 3 years | +15.70% | +59.87% |
| Market cap | $190.4B | $33.1B |
| P/E | 40.9 | 21.4 |
| P/S | 3.95 | 5.77 |
| P/B | 3.73 | 5.56 |
| Revenue growth | +10.00% | +9.00% |
| EPS growth | -66.20% | +12.40% |
| Gross margin % | 56.9 | 61.1 |
| Net margin % | 9.7 | 27.8 |
| ROE % | 9.2 | 26.8 |
| Debt / equity | 0.61 | 0.07 |
| FCF yield % | 3.5 | 4.9 |
| Dividend yield % | 2.29 | 1.05 |
| Beta | 0.06 | 0.47 |
| RSI (14) | 58.5 | 48.3 |
| Technical rating |